Irene Altabás-González

Irene Altabás-González

Auto-generated profile, based on publicly available information

Irene Altabás-González

Rheumatology Department, University Hospital Complex of Vigo, Vigo, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CRCarlos Rafael-Vidal
Carlos Rafael-Vidal
NPNair Pérez
Nair Pérez
IAIrene Altabás
Irene Altabás
Samuel Garcia PerezSamuel Garcia Perez
Samuel Garcia Perez
JPJose M. Pego-Reigosa
Jose M. Pego-Reigosa
Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option.

Verified
Journal Article
Open access
PDF file
CRCarlos Rafael-Vidal
Carlos Rafael-Vidal
IAIrene Altabás
Irene Altabás
NPNair Pérez
Nair Pérez
CRCoral Mourino Rodríguez
Coral Mourino Rodríguez
JPJose M. Pego-Reigosa
Jose M. Pego-Reigosa
Samuel Garcia PerezSamuel Garcia Perez
Samuel Garcia Perez
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical presentations that can affect almost all organ systems. Lupus nephritis (LN) is a severe complication that affects approximately half of the systemic erythematosus lupus (SLE) patients, which significantly increases the morbidity and the mortality risk. LN is characterized by the accumulation of immune complexes, ultimately leading to renal failure. Aberrant activation of T cells plays a critical role in the pathogenesis of both SLE and LN and is involved in the production of inflammatory cytokines, the recruitment of inflammatory cells to the affected tissues and the co-stimulation of B cells. Calcineurin is a serine-threonine phosphatase that, as a consequence of the T cell hyperactivation, induces the production of inflammatory mediators. Moreover, calcineurin is also involved in the alterations of the podocyte phenotype, which contribute to proteinuria and kidney damage observed in LN patients. Therefore, calcineurin inhibitors have been postulated as a potential treatment strategy in LN, since they reduce T cell activation and promote podocyte cytoskeleton stabilization, both being key aspects in the development of LN. Here, we review the role of calcineurin in SLE and the latest findings about calcineurin inhibitors and their mechanisms of action in the treatment of LN.

3 August 2024 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
IAIrene Altabás-González
Irene Altabás-González
IRIñigo Rua-Figueroa
Iñigo Rua-Figueroa
CMCoral Mouriño
Coral Mouriño
KRKaren Roberts
Karen Roberts
NJNorman Jimenez
Norman Jimenez
JPJosé M Pego-Reigosa
José M Pego-Reigosa
Objective To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort. Methods Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We longitudinally analysed SDI (globally and for each domain) over time only in the 1274 patients whose dates of damage events had been recorded. Results During the first year after diagnosis of SLE, 20% of the 1274 patients presented with new damage manifestations. At years 2 and 3, new damage was recorded in 11% and 9% of patients. The annual percentage of patients with new damage after year 5 decreased to 5%. In the first year with the disease, most damage was accumulated in the musculoskeletal, neuropsychiatric and renal systems; in later stages, most damage was in the musculoskeletal, ocular and cardiovascular systems. Considering ‘cerebrovascular accident’ and ‘claudication for 6 months’ as cardiovascular items, the cardiovascular system was the second most affected system during the early stages of SLE, with 19% of the patients who presented with damage affected at first year after diagnosis. During the late stages, 20–25% of the patients presenting with new damage did so in this modified cardiovascular domain of the SDI. Conclusions New damage occurs mainly during the first year following diagnosis of SLE. Cardiovascular damage is relevant in both the early and the late stages of the disease. Strategies to prevent cardiovascular damage should be implemented early after diagnosis of SLE.

6 August 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
OROlga Rusinovich-Lovgach
Olga Rusinovich-Lovgach
ZPZulema Plaza
Zulema Plaza
MFMónica Fernández-Castro
Mónica Fernández-Castro
JSJose Rosas-Gómez de Salazar
Jose Rosas-Gómez de Salazar
VMVictor Manuel Martinez-Taboada
Victor Manuel Martinez-Taboada
JAJosé Luis Andréu
José Luis Andréu

4 May 2025 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
OROlga Rusinovich-Lovgach
Olga Rusinovich-Lovgach
ZPZulema Plaza
Zulema Plaza
MCMónica Fernández Castro
Mónica Fernández Castro
JSJose Rosas-Gómez de Salazar
Jose Rosas-Gómez de Salazar
VMVictor Manuel Martinez-Taboada
Victor Manuel Martinez-Taboada
JSJosé Luis Andréu Sánchez
José Luis Andréu Sánchez

27 January 2026 in Lupus Science & Medicine
Verified
Journal Article
Open access
PVPaola Vidal-Montal
Paola Vidal-Montal
AFAina Fabregat
Aina Fabregat
IAIrene Altabás-González
Irene Altabás-González
JPJosé María Pego-Reigosa
José María Pego-Reigosa
AHAndrea Hernández-Martínez
Andrea Hernández-Martínez
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
Objective: To evaluate the efficacy, safety and predictive factors of belimumab (BEL)-based triple therapy in proliferative lupus nephritis (LN) in real-world settings. Methods: We conducted a multicentre, retrospective study including patients with proliferative LN (new-onset or relapsing) who initiated BEL within 6 months of a renal flare, in combination with standard-of-care. Results: 49 patients were included (mean age 37 years; 85.7% female; 67.3% Caucasian). The median time from renal flare to BEL initiation was 1 month (IQR 0–3). By 12 months, 67.3% achieved complete renal response (CRR), 75.5% primary efficacy renal response (PERR) and 83.7% at least partial renal response. Median proteinuria declined from 2.7 g/day to 0.49 g/day, with parallel improvement in estimated glomerular filtration rate (71 to 78 mL/min/1.73 m²). Patients with baseline proteinuria <3 g/day achieved significantly higher CRR (78.1% vs 47.1%; p=0.027) and PERR (84.4% vs 58.8%; p=0.048) rates. The mean glucocorticoid (GC) dose decreased from 31.7 mg/day at baseline to 3.5 mg/day at 12 months, and 26.1% of patients achieved complete GC withdrawal. Extrarenal disease activity was present in 81.6% of patients at baseline, predominantly articular and mucocutaneous, with clinically meaningful improvement in 80% during follow-up. At 12 months, 40.8% met remission by Definition Of Remission In Systemic Lupus Erythematosus (DORIS) criteria and 46.9% attained Lupus Low Disease Activity State (LLDAS). Renal treatment failure occurred in 16.3% and renal relapse in 4.1%. Adverse events were mild, and no serious BEL-related events were observed. Conclusion: BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.